Option Pricing and Risk Hedging in Current Financial Market:
A Case for Pfizer
Hang Zhang
Liberal Arts & Sciences, University of Connecticut, l22 Eastwood Rd, Storrs, CT, 06268, U.S.A.
Keywords: BS, BT, Option Pricing, Pfizer.
Abstract: The research background of this paper is that in stock option trading, the risk is weakened, and the profit
level is improved by means of hedging. This paper discusses and analyzes the differences in the hedging
results of stock options of the same company based on different option pricing models. The data adopts the
stock option trading data of Pfizer, and uses the historical data model, BS (black-Scholes) model, and BT
(Binomial Tree) model to construct an option pricing model and calibrate it, and finally perform delta
hedging. The results show that the historical data model shows the best results in the final hedging, the
hedging results of the BS model are in the middle level, while the hedging results of the BT model are not
satisfactory in this study. This research appears in stock option trading, and the investment behavior of
single company stock option as the target weakens the comprehensive risk and improves the comprehensive
profit level.
1 INTRODUCTION
Beginning in the second half of 2019, Covid-19
spread recklessly around the world, which has
brought huge negative impact on people's daily life
and production and construction. With the
development and production of vaccines and antiviral
drugs, people are working hard to fight and defeat the
virus. In this process, pharmaceutical companies
have become bridgeheads to overcome difficulties,
and have introduced a large amount of funds for
scientific research and development and drug
production. Therefore, in the post-epidemic era,
companies in the field of big health are generally
beneficial. As one of the top pharmaceutical
companies, Pfizer has become the most favored
company by investors in the pharmaceutical industry.
However, with the influx of more and more
investors, the phenomenon of blind investment and
follow-up buying continues to appear. People are
superstitious about the long-term benefits of the
pharmaceutical industry, while ignoring the objective
risks in stock option trading. Therefore, it is very
important to choose a suitable option pricing model
and a reasonable hedging strategy, which will help to
reduce risks and improve returns.
The research on stock option pricing model and
hedging strategy is not a new topic in the industry.
Around this center, in the current field, many
scholars have expressed their views on option pricing
models and their understanding of hedging strategies.
Li Xu, Shijie Deng, Valerie M. Thomas co-published
article and hold the idea that options that the impact
of market volatility on option prices is divided into
effectiveness and destructiveness (Xu, 2016).
Ghulam Sarwar wrote that there is contemporaneous
positive feedback between the volatility of the
exchange rate and the trading volume of call and put
options (Sarwar, 2003). The paper completed by Jie
cao and Bing Han pointed out that when using delta
to hedge stock options, as the heterogeneous
volatility of the underlying stock increases, returns
show a monotonically decreasing trend (Cao, 2013).
Research by Gurdip Bakshi and Nikunj Kapadia
found that delta-hedged portfolio returns are
correlated with changes in the volatility risk premium
(Bakshi, 2003). When Erik Ekström and Johan Tysk
studied stochastic volatility and the Black-Scholes
equation, they found that option prices are the only
classical solution to parabolic differential equations,
and this solution is bounded (Ekström, 2010). Yisong
Tian's research pointed out that the calibrated
binomial model can recalibrate the binary tree
through the skew parameter, this method allows the
Zhang, H.